NCT06975371View on ClinicalTrials.gov

Real-World Outcomes of Patients With Metastatic Breast Cancer After Treatment With First-Line ET+CDK4/6i

CompletedOBSERVATIONAL
Enrollment

1,415

Participants

Timeline

Start Date

April 14, 2025

Primary Completion Date

May 8, 2025

Study Completion Date

August 5, 2025

Conditions
Advanced/Metastatic HER2-negative Breast Cancer
Interventions
OTHER

No drug

No study drug was administered in this non-interventional study.

Trial Locations (1)

10013

Flatiron Health, Inc, New York

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY